Published in JAMA Oncol on June 01, 2016
KRAS in Non-Small-Cell Lung Cancer: Oncogenic Addiction and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. JAMA Oncol (2016) 1.08
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res (2016) 0.76
Population effect model identifies gene expression predictors of survival outcomes in lung adenocarcinoma for both Caucasian and Asian patients. PLoS One (2017) 0.75
KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol (2016) 0.75
Generics have a chequered recent history. BMJ (2016) 0.75
Molecular Testing of Lung Cancers. J Pathol Transl Med (2017) 0.75